Showing results 1 to 20 of 34
next >
| Issue Date | Title | Author(s) |
| 2018 | Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung | Lu, Shun; Li, Wei; Zhou, Caicun; Hu, Cheng-Ping; Qin, Shukui; Cheng, Gang; Feng, Jifeng; Wang, Jie; Cseh, Agnieszka; Peil, Barbara; Gibson, Neil; Ehrnrooth, Eva; Zhang, Li |
| 20-May-2020 | Analysis of canonical and noncanonical splicing site mutation of MET that causes exon 14 skipping. | Yu, Yongfeng; Chen, Rongrong; Zhao, Jun; Yi, Xin; Lu, Shun |
| Apr-2020 | Circulating tumor DNA clearance predicts prognosis across treatment regimen in a large real-world longitudinally monitored advanced non-small cell lung cancer cohort | Song, Yong; Hu, Chengping; Xie, Zhanhong; Wu, Lin; Zhu, Zhengfei; Rao, Chuangzhou; Liu, Li; Chen, Yuan; Liang, Naixin; Chen, Jun; Hu, Chunhong; Yang, Nong; Hu, Jie; Zhao, Weixin; Tong, Gangling; Dong, Xiaorong; Zheng, Di; Jin, Meiling; Chen, Jianhua; Huang, Meijuan; He, Yong; Rosell, Rafael; Lippi, Giuseppe; Mino-Kenudson, Mari; Han-Zhang, Han; Mao, Xinru; Zhang, Lu; Liu, Hao; Field, John K.; Chuai, Shannon; Ye, Junyi; Han, Yusheng; Lu, Shun |
| Jul-2022 | Comprehensive analysis of MET mutations in NSCLC patients in a real-world setting | Ai, Xinghao; Yu, Yongfeng; Zhao, Jun; Sheng, Wang; Bai, Jing; Fan, Zaiwen; Liu, Xuemei; Ji, Wenxiang; Chen, Rongrong; Lu, Shun |
| 2018 | A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel | Wu, Yi-Long; Wang, Chang-Li; Liao, Mei-Lin; Guan, Zhong-Zhen; Gao, Chen-Yan; Lu, Shun; Zhao, Ming-Fang; Wang, Jie; Liu, Xiao-Qing; Yang, Jin-Ji; Liang, Jun; Mao, Wei-Min; Han, Bao-Hui; Zhang, Xu-Chao; Song, Yong; Feng, Ji-Feng; Ma, Sheng-Lin; Wu, Gang; Zhou, Cai-Cun; Chen, Ke-Neng; Cheng, Ying; He, Yong; Chen, Chun; Wang, Qun; Lin, Ji-Zhen; Zhu, Bo; Liu, Yun-Peng; Hu, Yi; Qiao, Gui-Bin; Zhou, Qing; Song, Qi-Bin; Wu, Nan; Wu, Lin; Huang, Cheng; Fu, Xiao-Long; Xiong, Jian-Ping; Hu, Jie; Hu, Cheng-Ping; Chang, Jian-Hua; Zhao, Qiong; Zhao, Jun; Zhou, |
| 2017 | A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel | Wu, Yi-Long; Wang, Chang-Li; Sun, Yan; Liao, Mei-Lin; Guan, Zhong-Zhen; Yang, Zhi-Min; Zhou, Qing-Hua; Lu, Shun; Cheng, Ying; Liu, Xiao-Qing; Zhang, Xu-Chao; Zhou, Caicun; Wang, Jie; Zhou, Qing; Song, Yong; Han, Bao-Hui; Ma, Zhi-Yong; Yang, Fan; Wang, Qun; Chuai, Shao-Kun; Shao, Yang; He, Wei; Zhu, Guanshan; Xiong, Lei; Wang, Jian-Jun; Chen, Ke-Neng; Zhang, Li; Mao, Wei-Min; Ma, Sheng-Lin; Feng, Ji-Feng; Yang, Xue-Ning; Xu, Lin; Chen, Gang; Zhao, Jian; Song, Qi-Bin; Shen-Tu, Yang; Qiao, Gui-Bin; Yu, Ding; Yu, Shi-Ying; Hu, Yi; Chen, Ming; Chen, Go |
| Dec-2024 | Consensus on the lung cancer management after third-generation EGFR-TKI resistance | Zhou, Qing; Zhao, Hongyun; Lu, Shun; Cheng, Ying; Liu, Ying; Zhao, Mingfang; Yu, Zhuang; Hu, Chengping; Zhang, Li; Yang, Fan; Zhao, Jun; Guo, Renhua; Ma, Rui; Du, Yingying; Dong, Xiaorong; Cui, Jiuwei; Tan, Daniel S. W.; Ahn, Myung-Ju; Tsuboi, Masahiro; Liu, Si-Yang Maggie; Mok, Tony S.; Wu, Yi-Long |
| Jul-2021 | ctDNA analysis in the savolitinib phase II study in Non-Small Cell Lung Cancer (NSCLC) patients (pts) harboring MET exon 14 skipping alterations (METex14). | Yu, Yongfeng; Ren, Yongxin; Fang, Jian; Cao, Lejie; Liang, Zongan; Guo, Qisen; Han, Sen; Ji, Zimei; Wang, Ye; Sun, Yulan; Chen, Yuan; Li, Xingya; Xu, Hua; Zhou, Jianying; Jiang, Liyan; Cheng, Ying; Han, Zhigang; Shi, Jianhua; Chen, Gongyan; Ma, Rui; Fan, Yun; Sun, Sanyuan; Jiao, Longxian; Jia, Xiaoyun; Wang, Linfang; Lu, Puhan; Li, Jing; Xu, Qian; Luo, Xian; Su, Weiguo; Lu, Shun |
| Jul-2021 | D-0316 in patients with advanced T790M-positive EGFR-mutant non-small cell lung cancer who progressed on prior EGFR-TKI therapy: results from a phase II study (NCT03861156). | Lu, Shun; Zhang, Yiping; Zhang, Guojun; Zhou, Jianying; Cang, Shundong; Cheng, Ying; Wu, Gang; Cao, Peiguo; Lv, Dongqing; Jin, Xiangming; Jian, Hong; Chen, Chengshui; Jiang, Guanming; Tian, Panwen; Wang, Kai; Zhao, Hui; Chen, Gongyan; Chen, Qun; Ding, Cuimin; Yang, Junquan; Guo, Renhua; Sun, Guoping; Wang, Bin; Jiang, Liyan; Zhuang, Wu; Liu, Zhe; Fang, Jian; Liu, Yunpeng; Zhang, Jian; Chen, Jun; Pan, Yueyin; Yu, Qitao; Zhao, Min; Cui, Jiuwei; Li, Dianming; Yi, Tienan; Yu, Zhuang; Yang, Yan; Zhang, Yan; Zhi, Xiuyi; Huang, Yunchao; Wu, Rong; Chen, Liangan; Zang, Aimin; Cao, Lejie; Li, Qingshan; Li, Xiaoling; Song, Yong; Wang, Donglin; Zhang, Shucai |
| Aug-2021 | Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study | Ai, Xinghao; Pan, Yueyin; Shi, Jianhua; Yang, Nong; Liu, Chunling; Zhou, Jianying; Zhang, Xiaodong; Dong, Xiaorong; He, Jianxing; Li, Xiaoling; Chen, Gongyan; Li, Xingya; Zhang, Helong; Liao, Wangjun; Zhang, Yiping; Ma, Zhiyong; Jiang, Liyan; Cui, Jiuwei; Hu, Chunhong; Wang, Wei; Huang, Cheng; Zhao, Jun; Ding, Cuimin; Hu, Xiaohua; Wang, Kai; Gao, Beili; Song, Yong; Liu, Xiaoqing; Xiong, Jianping; Liu, Anwen; Li, Junling; Liu, Zhe; Li, Yinyin; Wang, Mengzhao; Zhang, Biao; Zhang, Dan; Lu, Shun |
| 30-Jun-2023 | Efficacy, safety and pharmacokinetics of Unecritinib (TQ-B3101) for patients with ROS1 positive advanced non-small cell lung cancer: a Phase I/II Trial | Lu, Shun; Pan, Hongming; Wu, Lin; Yao, Yu; He, Jianxing; Wang, Yan; Wang, Xiuwen; Fang, Yong; Zhou, Zhen; Wang, Xicheng; Cai, Xiuyu; Yu, Yan; Ma, Zhiyong; Min, Xuhong; Yang, Zhixiong; Cao, Lejie; Yang, Huaping; Shu, Yongqian; Zhuang, Wu; Cang, Shundong; Fang, Jian; Li, Kai; Yu, Zhuang; Cui, Jiuwei; Zhang, Yang; Li, Man; Wen, Xinxuan; Zhang, Jie; Li, Weidong; Shi, Jianhua; Xu, Xingxiang; Zhong, Diansheng; Wang, Tao; Zhu, Jiajia |
| 2011 | Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study | Zhou, Caicun; Wu, Yi-Long; Chen, Gongyan; Feng, Jifeng; Liu, Xiao-Qing; Wang, Changli; Zhang, Shucai; Wang, Jie; Zhou, Songwen; Ren, Shengxiang; Lu, Shun; Zhang, Li; Hu, Chengping; Hu, Chunhong; Luo, Yi; Chen, Lei; Ye, Ming; Huang, Jianan; Zhi, Xiuyi; Zhang, Yiping; Xiu, Qingyu; Ma, Jun; Zhang, Li; You, Changxuan |
| Apr-2023 | Event-free survival (EFS) with neoadjuvant nivolumab (NIVO) plus platinum- doublet chemotherapy (chemo) versus chemo by surgical outcomes in resectable non-small cell lung cancer (NSCLC) from CheckMate 816 | Spicer, Jonathan; Wang, Changli; Tanaka, Fumihiro; Chen, Ke-Neng; Ito, Hiroyuki; Liberman, Moishe; Chen, Qixun; Girard, Nicolas; Lu, Shun; Provencio, Mariano; Mitsudomi, Tetsuya; Awad, Mark; Felip, Enriqueta; Swanson, Scott; Forde, Patrick; Cai, Junliang; Mahmood, Javed; Hu, Nan; Tran, Phuong; Broderick, Stephen |
| 2005 | Heterogeneity in predisposition of hepatic cells to be induced into pancreatic endocrine cells by PDX-1 | Lu, Shun; Wang, Wei-Ping; Wang, Xiao-Fei; Zheng, Zong-Mei; Chen, Ping; Ma, Kang-Tao; Zhou, Chun-Yan |
| Apr-2024 | IMpower210: A phase III study of second-line atezolizumab vs. docetaxel in East Asian patients with non-small cell lung cancer | Wu, Yi-Long; Lu, Shun; Chen, Gongyan; He, Jianxing; Feng, Jifeng; Zhang, Yiping; Jiang, Liyan; Pan, Hongming; Chang, Jianhua; Fang, Jian; Cai, Amy; Bu, Lilian; Shi, Jane; Xia, Jinjing |
| 2016 | Meta-Analysis of First-Line Pemetrexed Plus Platinum Treatment in Compared to Other Platinum-Based Doublet Regimens in Elderly East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer | Lu, Shun; Cheng, Ying; Zhou, Cai-cun; Wang, Jie; Yang, James Chih-Hsin; Zhang, Ping-hai; Zhang, Xiao-qing; Wang, Xin; Orlando, Mauro; Wu, Yi-long |
| 2018 | Nedaplatin Plus Docetaxel Versus Cisplatin Plus Docetaxel as First-Line Chemotherapy for Advanced Squamous Cell Carcinoma of the Lung - A Multicenter, Open-label, Randomized, Phase III Trial | Lu, Shun; Chen, Zhiwei; Hu, Chengping; Zhang, Jian; Chen, Yuan; Song, Yong; Zhao, Qiong; Fan, Yun; Wu, Gang; Ma, Zhiyong; Fang, Jian; Yu, Qitao; Liu, Zhe |
| Apr-2022 | Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer | Forde, Patrick M.; Spicer, Jonathan; Lu, Shun; Provencio, Mariano; Mitsudomi, Tetsuya; Awad, Mark M.; Felip, Enriqueta; Broderick, Stephen R.; Brahmer, Julie R.; Swanson, Scott J.; Kerr, Keith; Wang, Changli; Ciuleanu, Tudor-Eliade; Saylors, Gene B.; Tanaka, Fumihiro; Ito, Hiroyuki; Chen, Ke-Neng; Liberman, Moishe; Vokes, Everett E.; Taube, Janis M.; Dorange, Cecile; Cai, Junliang; Fiore, Joseph; Jarkowski, Anthony; Balli, David; Sausen, Mark; Pandya, Dimple; Calvet, Christophe Y.; Girard, Nicolas |
| Jul-2021 | Nivolumab (NIVO) plus platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment (tx) for resectable (IB-IIIA) non-small cell lung cancer (NSCLC) in the phase 3 CheckMate 816 trial. | Forde, Patrick M.; Spicer, Jonathan; Lu, Shun; Provencio, Mariano; Mitsudomi, Tetsuya; Awad, Mark M.; Felip, Enriqueta; Broderick, Stephen; Brahmer, Julie; Swanson, Scott J.; Kerr, Keith; Wang, Changli; Saylors, Gene B.; Tanaka, Fumihiro; Ito, Hiroyuki; Chen, Ke-Neng; Dorange, Cecile; Cai, Junliang; Fiore, Joseph; Girard, Nicholas |
| 16-Dec-2024 | Noninvasive early identification of durable clinical benefit from immune checkpoint inhibition: a prospective multicenter study (NCT04566432) | Ai, Xinghao; Jia, Bo; He, Zhiyi; Zhang, Junping; Zhuo, Minglei; Zhao, Jun; Wang, Zhe; Zhang, Jiexia; Fan, Zaiwen; Zhang, Xiaotong; Li, Chong; Jin, Feng; Li, Ziming; Ma, Xia; Tang, Hao; Yan, Xiang; Li, Wei; Xiong, Yuanyuan; Yin, Huan; Chen, Rongrong; Lu, Shun |
